Literature DB >> 16957763

The diagnosis and management of asymptomatic primary hyperparathyroidism.

Shonni J Silverberg1, John P Bilezikian.   

Abstract

Classical primary hyperparathyroidism--a disease of 'bones, stones, and psychic groans'--is a rarity in the US, although it is still seen in some parts of the world. Today, most patients with primary hyperparathyroidism are asymptomatic. This change in clinical profile is not merely because of improved detection techniques, and patients with primary hyperparathyroidism who lack symptoms, if left untreated, rarely develop the 'classical' features that were common previously. Indeed, currently available data suggest that there is, today, a disorder with different, yet characteristic, effects on the end-organs of the hyperparathyroid process. In this review, the features of the skeletal, renal, neuropsychologic, cardiovascular, and gastrointestinal manifestations of 'asymptomatic' primary hyperparathyroidism will be discussed. The considerable body of data that has emerged since the recognition of the new clinical profile of primary hyperparathyroidism has allowed a reconsideration of standards of care for this disease. These data were reviewed and incorporated into new clinical guidelines at the 2002 NIH workshop on asymptomatic primary hyperparathyroidism. These recommendations highlight both what is known about the disease, and important areas that need investigation. Continued interest in the skeletal, cardiovascular, and neuropsychiatric manifestations of the disease, and therapeutic trials of medical approaches for its management, will further refine our current understanding, and could lead to additional modifications in the approach to patients with this common endocrine disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957763     DOI: 10.1038/ncpendmet0265

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN: 1745-8366


  23 in total

1.  Elevated parathyroid hormone after parathyroidectomy delays symptom improvement.

Authors:  Priya R Pathak; Sara E Holden; Sarah C Schaefer; Glen Leverson; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2014-03-02       Impact factor: 2.192

Review 2.  Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.

Authors:  Desmond Padhi; Robert Harris
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  [Recurrence prevention of kidney stone disease].

Authors:  M Straub
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

4.  GCM2-Activating Mutations in Familial Isolated Hyperparathyroidism.

Authors:  Bin Guan; James M Welch; Julie C Sapp; Hua Ling; Yulong Li; Jennifer J Johnston; Electron Kebebew; Leslie G Biesecker; William F Simonds; Stephen J Marx; Sunita K Agarwal
Journal:  Am J Hum Genet       Date:  2016-10-13       Impact factor: 11.025

Review 5.  Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

Authors:  Leonidas H Duntas; Nikolaos Stathatos
Journal:  Endocrine       Date:  2011-03-26       Impact factor: 3.633

6.  Current concepts in the management of primary hyperparathyroidism.

Authors:  N Gopalakrishna Iyer; Ashok R Shaha
Journal:  Indian J Surg Oncol       Date:  2010-11-21

7.  Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.

Authors:  R Cesareo; E Di Stasio; F Vescini; G Campagna; R Cianni; V Pasqualini; F Romitelli; F Grimaldi; S Manfrini; A Palermo
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

Review 8.  Parathyroid cancer.

Authors:  John M Sharretts; Electron Kebebew; William F Simonds
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

Review 9.  [Surgical resection of the thyroid and parathyroid glands].

Authors:  U Woenckhaus; R Büttner; L C Bollheimer
Journal:  Internist (Berl)       Date:  2007-06       Impact factor: 0.743

Review 10.  Asymptomatic primary hyperparathyroidism.

Authors:  Shonni J Silverberg; Marcella D Walker; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.